This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Shire plc: Reported To Hire Takeover Adviser

Stocks in this article: AGN SHP.L SHPG SHPGF VRX

By Alex Gavrish, Etalon Investment Research; author of "Wall Street Back To Basics"

Shire

Shire hires takeover adviser

On June 16th, 2014, Reuters reported that drugmaker Shire PLC ADR (SHPG) (SHP) has hired investment bank Citigroup Inc (C) to help defend itself against takeover bids. Company expects to be approached by potential bidders in light of a recent wave of deals in the healthcare sector. For example, according to media reports Shire was approached by Allergan, Inc. (AGN) few months before Allergan itself became subject of a takeover bid by Valeant Pharmaceuticals Intl Inc (VRX) (VRX). Shire might be an attractive target for US firms as it is domiciled in Ireland and enjoys low corporate tax rate.

ViroPharma acquisition

During January 2014, Shire completed aquisition of Viropharma Inc (VPHM) for approximately $3.8 billion. The acquisition added CINRYZE to Shire's portfolio of currently marketed products. CINRYZE is a leading brand for the prophylactic treatment of Hereditary Angioedema "HAE" in adolescents and adults. ViroPharma will bring Shire two additional marketed products and other pipeline assets. According to guidance provided by ViroPharma’s management at the time of acquisition, sales in FY 2014 are projected to be $584 millon and EBITDA $166 million. Shire also expects to achieve annual cost synergies of approximately $150 million by 2015. Based on these estimates, Shire paid an EV/EBITDA multiple of approximately x12 in the transaction.

Company profile

Shire plc is a leading specialty biopharmaceutical company that focuses on developing and marketing innovative specialty medicines that address significant unmet patient needs. The company has grown through acquisitions, completing a series of major transactions that have brought therapeutic, geographic and pipeline growth and diversification. Shire has four commercial unitsin the following specialist therapeutic areas: Rare Diseases, Neuroscience, Gastrointestinal GI and Internal Medicine.

Current valuation

Based on a recent share price, Shire had maket capitalization of $36.3 billion and enterprise value of $37.7 billion. Company is currently valued at an estimated EV/EBITDA multiple of x15 FY 2014 Q1 annualized EBITDA. During first quarter of 2014, Shire generated $246 million in cash flow from operations and $231 million in free cash flow. On June 18th, 2014, Bloomberg reported that according to some analysts Allergan might make a takeover bid for Shire in the near future in order to defend itself against takeover by Valeant. Possible surprise in the form of takeover, reasonable valuation, and attractive growth prospects make Shire an interesting candidate for long-term investor .

The post Shire plc: Reported To Hire Takeover Adviser appeared first on ValueWalk.

-By Alex Gavrish

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs